MicroVue™ BAP EIA

The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.


Product Specifications

Citations 21
Specimen

Serum 20 μL

LLOQ 2 U/L
ULOQ 140 U/L
Assay Time 3.5 hours
Cross Reactivity

Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep

Ordering Information

For In Vitro Diagnostic Use.
Catalog Number 8012
Catalog Number (CE)  
Size 96 wells/test
Price (USD) $995.00
Price (EURO) 700,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Serum 20 μL
Limit of Detection (LOD) 0.7 U/L
Lower Limit of Quantitation (LLOQ) 2 U/L
Upper Limit of Quantitation (ULOQ) 140 U/L
Intra Assay 3.9–5.8%
Inter Assay 5.0–7.6%
Standards 6
Controls 2
Sample Values

Females (Ages 25–44) 11.6–29.6 U/L, Males (Ages ≥25) 15.0–41.3 U/L

Assay Time 3.5 hours
Cross Reactivity

Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep

Storage

Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components

Background

BAP is an enzyme produced by osteoblasts, the cells responsible for bone formation. The MicroVue BAP immunoassay provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum as an indicator of osteoblastic activity. Measurement of BAP is intended for use as an aid in the 1) management of postmenopausal osteoporosis and Paget's disease, 2) monitoring of postmenopausal women on hormonal or bisphosphonate therapy, and 3) prediction of skeletal response to hormonal therapy in postmenopausal women.